CTOs on the Move

Umoja Biopharma

www.umoja-biopharma.com

 
Umoja is developing a new approach to cancer therapy that retools a patient`s immune system in vivo, enhancing the body`s natural capacity to fight cancer. We envision a world where all patients with cancer have access to the most advanced immunotherapies and are free from the burdens of traditional cancer therapies.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Umoja Biopharma raised $53M on 11/18/2020
Umoja Biopharma raised $210M on 06/15/2021

Similar Companies

Fagron US

Fagron NV is a publicly traded multinational group of companies governed by Belgian law.

Recursion

Recursion is a clinical-stage biotechnology company combining experimental biology and automation with artificial intelligence in a massively parallel system to efficiently discover potential drugs for diverse indications, including genetic disease, inflammation, immunology, and infectious disease. Recursion applies causative perturbations to human cells to generate disease models and associated biological image data. Recursion`s rich, relatable database of more than a petabyte of biological images generated in-house on the company`s robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics to radically improve lives. Recursion is headquartered in Salt Lake City.

United BioSource

Dedicated to Global Product Safety, Brand Loyalty, and Patient Access Strategies that Support the Full Product Lifecycle United BioSource LLC (UBC) is a leading provider of pharmaceutical support services, partnering with life science companies to make medicine and medical products safer and more accessible. Our diverse suite of services helps bridge the gap between development and delivery and builds brand loyalty through patient access and adherence. UBC is well known for our ability to generate authoritative, real-world evidence of product effectiveness, safety, and value to assist healthcare decisions and enhance patient care. Developing a drug, taking it through commercialization, and demonstrating its post-launch value and safety is a complex journey. Regulatory hurdles and payer decision-making are increasing the complexity around drug development and product choices. UBC has aligned our expertise and industry insight to help manufacturers make informed decisions early in the product journey that ultimately optimize care and improve patient outcomes. The most successful product journeys start with great maps. UBC`s industry-leading experts work in unison to effectively navigate the product lifecycle, focusing on: Clinical Development Safety Commercialization We understand what it takes to compete in a crowded product market with many stakeholders that demand the right evidence at the right time. Our Past, Present, and Our Future UBC was founded in 2003 by industry experts with a passion for innovation and a commitment to working with pharmaceutical and biotech organizations in proving the safety, efficacy, and value of pharmaceutical and medical products. We recognized the opportunity to build an organization tailored to meet the need for scientific evidence in the healthcare industry. And, we quickly developed our core strength – the generation, analysis, and communication of real-world evidence throughout the product lifecycle.

Paddock Laboratories Inc

Paddock Laboratories is a privately-held niche-based pharmaceutical company located in Minneapolis, Minnesota. Bruce Paddock, President, founded the business in 1977 with only three employees. Today, Paddock employs over 250 people in the areas of

Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients` needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).